Regenerative Medicine

Galapagos expands business

Thursday 23 June 2022
Country
Netherlands

Galapagos NV is to acquire two companies with a presence in cell therapy as it takes steps to broaden its business under new leadership. The Dutch company has reached separate agreements to purchase CellPoint BV, a manufacturing company in the Netherlands, and AboundBio Inc, a US drug discovery company with an antibody library and antibody engineering capabilities.

Gene therapy manufacture

Monday 13 June 2022
Country
France

Two French companies have joined forces to co-develop manufacturing technologies for AAV-based gene therapies. Coave Therapeutics is to contribute its expertise on viral vectors to the collaboration, while ABL, a contract development and manufacturing organisation, will provide production skills and laboratory space in Lyon.

Kymriah data show durable remission

Sunday 12 June 2022
Country
Switzerland

New data for Kymriah (tisagenlecleucel), the first chimeric antigen receptor (CAR) T cell therapy to be approved for a cancer, have shown durable remission and long-term survival for the children and young adults treated with the therapy. The developer, Novartis, presented the data at the 2022 European Hematology Association Hybrid Congress on 12 June.

Venture finance for non-viral genetic medicines

Tuesday 7 June 2022
Country
United States

A syndicate of international investors has raised $75 million for Code Biotherapeutics Inc, a US company developing genetic medicines using a synthetic DNA delivery platform. The delivery technology is different from the conventional viral vector and is described by its developer as versatile and unimpaired by concerns about immunogenicity.

Funding for mitochondrial therapy

Tuesday 7 June 2022
Country
Japan

A Japanese company specialising in advanced therapies has received $30.3 million in Series B funding to advance a programme in tissue and organ repair. LUCA Science Inc is working on a mitochondrial replacement therapy that would restore cellular energy flow in damaged tissues and organs.

Immatics, BMS in new deal

Sunday 5 June 2022
Country
Germany

Germany-based Immatics NV is to make its cell therapy platform available to Bristol Myers Squibb Co in order to develop a further cohort of immunotherapies for cancer. The collaboration, announced on 2 June, is an expansion of an existing partnership aimed at developing off-the-shelf cell therapies for solid tumours.

Evotec acquires cell therapy manufacturer

Tuesday 31 May 2022
Country
Germany

Evotec SE has expanded its capabilities in the field of cell therapy with the acquisition of the Italian company Rigenerand Srl, a 2009 spin-off of the University of Modena and Reggio Emilia. The acquisition, valued at €23 million, comes within weeks of Evotec’s agreement with Sernova Corp of Canada to develop a beta cell replacement therapy for diabetes. The prospective therapy will use induced pluripotent stem (iPS) cells produced by Evotec, combined with a pouch developed by Sernova.

Gene therapy for retinal disease

Saturday 23 April 2022
Country
Germany

A new gene therapy project has been launched by ViGeneron GmbH of Germany and Regeneron Pharmaceuticals Inc that would potentially result in the development of a treatment for an inherited retinal disorder. The two companies announced their collaboration on 6 April but did not identify the disease.

Gene therapy for myeloma

Tuesday 29 March 2022
Country
Netherlands

A cell-based gene therapy for multiple myeloma has been recommended by the European Medicines Agency for patients with multiple myeloma, an incurable blood cancer that causes plasma cells to grow out of control. Symptoms can include bone fracture or even kidney failure. The drug, Carvykti (ciltacabtagene autoleucel), is a chimeric antigen receptor (CAR) T cell medicine consisting of a patient’s own immune cells which have been engineered to target and kill cancer cells.

Novartis explores capsids

Tuesday 15 March 2022
Country
Switzerland

Novartis is to explore new ways of delivering gene therapies to the brain under a licence option agreement with Voyager Therapeutics Inc, a US company with adeno-associated virus (AAV) capsid technology. Under the agreement, the Swiss multinational may elect to license novel capsids for use in directing therapies against three undisclosed central nervous system (CNS) targets. Further out, it may exercise options for two additional targets. The goal is to develop gene therapies for neurological diseases that manifest in deep regions of the brain.